CO6270204A2 - Soluciones farmaceuticas orales que contienen telbivudina - Google Patents
Soluciones farmaceuticas orales que contienen telbivudinaInfo
- Publication number
- CO6270204A2 CO6270204A2 CO10002343A CO10002343A CO6270204A2 CO 6270204 A2 CO6270204 A2 CO 6270204A2 CO 10002343 A CO10002343 A CO 10002343A CO 10002343 A CO10002343 A CO 10002343A CO 6270204 A2 CO6270204 A2 CO 6270204A2
- Authority
- CO
- Colombia
- Prior art keywords
- oral solution
- milligrams
- milliliter
- solution according
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Una solucion oral que comprende de 20 a 50 miligramos/mililitro de telbivudina o tina sal farmacéuticamente aceptable de la misma, sacarina de sodio, cuando menos un agente mejorador/enmascarador de sabor, acido benzoico, y regulador de citrato.2.- Una solucion oral que comprende de 20 a 50 miligramos, mililitro de telbivudina o una sal farmacéuticamente aceptable de la misma, sacarina de sodio, cuando menos un agente mejorador/enmascarador de sabor, metil-parabeno sodico, propil-parabeno sodico, y regulador de citrato.3.- La solucion oral de acuerdo con cualquiera de las reivindicaciones anteriores, en donde esta solucion oral se regula hasta un intervalo de pH desde aproximadamente 3 hasta aproximadamente 5.4.- La solucion oral de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la sacarina de sodio mencionada esta presente en 0.2 miligramos/mililitro.5.- La solucion oral de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el agente mejorador/enmascarador de sabor es saborizante de fruta de la pasion.6.- La solucion oral de acuerdo con la Reivindicacion 5, en donde el saborizante de fruta de la pasion mencionado esta presente en 1.0 miligramos/mililitro.7.- La solucion oral de acuerdo con la Reivindicacion 1, en donde el acido benzoico mencionado esta presente en 1.5 miligramos/mililitro.8.- La solucion oral de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el regulador de citrato mencionado comprende 9.6 miligramos/mililitro de acido de citrato anhidro.9.- La solucion oral de acuerdo con la Reivindicacion 2, en donde el metilparabeno sodico mencionado esta presente en 1.0 miligramos/mililitro, y el propil-parabeno sodico mencionado esta presente en 0.2 miligramos/mililitro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07112381 | 2007-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270204A2 true CO6270204A2 (es) | 2011-04-20 |
Family
ID=38724394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10002343A CO6270204A2 (es) | 2007-07-12 | 2010-01-12 | Soluciones farmaceuticas orales que contienen telbivudina |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8445457B2 (es) |
| EP (1) | EP2178503A1 (es) |
| JP (1) | JP5314014B2 (es) |
| KR (3) | KR20140019040A (es) |
| CN (1) | CN101686938B (es) |
| AR (1) | AR067630A1 (es) |
| AU (1) | AU2008274170B2 (es) |
| BR (1) | BRPI0815562A2 (es) |
| CA (1) | CA2693609A1 (es) |
| CL (1) | CL2008002025A1 (es) |
| CO (1) | CO6270204A2 (es) |
| EC (1) | ECSP109871A (es) |
| IL (1) | IL202961A (es) |
| MA (1) | MA31507B1 (es) |
| MY (1) | MY147366A (es) |
| NZ (1) | NZ582443A (es) |
| PE (2) | PE20090476A1 (es) |
| RU (1) | RU2493826C2 (es) |
| TN (1) | TN2010000008A1 (es) |
| TW (1) | TW200911302A (es) |
| WO (1) | WO2009007426A1 (es) |
| ZA (1) | ZA200908993B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101960555B1 (ko) | 2011-05-13 | 2019-03-20 | 어레이 바이오파마 인크. | Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물 |
| US20140107130A1 (en) * | 2012-10-11 | 2014-04-17 | Antrim Pharmaceuticals, LLC | Oral Solution Formulations of Aripiprazole |
| WO2015175788A1 (en) | 2014-05-15 | 2015-11-19 | Array Biopharma Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| TWI609689B (zh) * | 2015-04-26 | 2018-01-01 | 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 | 改善腎臟病患者之腎臟功能和/或心臟功能的方法 |
| CN107550866A (zh) * | 2016-06-30 | 2018-01-09 | 康普药业股份有限公司 | 一种替比夫定制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856364A (en) | 1991-03-01 | 1999-01-05 | Warner Lambert Company | Therapeutic antiviral-wound healing compositions and methods for preparing and using same |
| EP1023899A1 (en) * | 1997-09-26 | 2000-08-02 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparation containing antiviral agent having purine or pyrimidine skeleton |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| PE20030545A1 (es) * | 2001-10-31 | 2003-06-19 | Schering Corp | Formulaciones de jarabe de ribavirina |
| TWI244393B (en) * | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
| US20090156545A1 (en) | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
-
2008
- 2008-07-10 JP JP2010515512A patent/JP5314014B2/ja not_active Expired - Fee Related
- 2008-07-10 KR KR1020147002720A patent/KR20140019040A/ko not_active Application Discontinuation
- 2008-07-10 EP EP08774979A patent/EP2178503A1/en not_active Withdrawn
- 2008-07-10 WO PCT/EP2008/059016 patent/WO2009007426A1/en active Application Filing
- 2008-07-10 KR KR1020127016214A patent/KR20120078754A/ko not_active Application Discontinuation
- 2008-07-10 AU AU2008274170A patent/AU2008274170B2/en not_active Ceased
- 2008-07-10 AR ARP080102959A patent/AR067630A1/es unknown
- 2008-07-10 KR KR1020107000530A patent/KR20100029829A/ko not_active Application Discontinuation
- 2008-07-10 NZ NZ582443A patent/NZ582443A/en not_active IP Right Cessation
- 2008-07-10 CA CA2693609A patent/CA2693609A1/en not_active Abandoned
- 2008-07-10 PE PE2008001158A patent/PE20090476A1/es not_active Application Discontinuation
- 2008-07-10 MY MYPI20095510A patent/MY147366A/en unknown
- 2008-07-10 CN CN2008800241250A patent/CN101686938B/zh active Active
- 2008-07-10 RU RU2010104395/15A patent/RU2493826C2/ru not_active IP Right Cessation
- 2008-07-10 PE PE2012002012A patent/PE20130180A1/es not_active Application Discontinuation
- 2008-07-10 BR BRPI0815562-3A2A patent/BRPI0815562A2/pt not_active IP Right Cessation
- 2008-07-10 US US12/667,975 patent/US8445457B2/en active Active
- 2008-07-11 CL CL2008002025A patent/CL2008002025A1/es unknown
- 2008-07-11 TW TW097126552A patent/TW200911302A/zh unknown
-
2009
- 2009-12-17 ZA ZA200908993A patent/ZA200908993B/xx unknown
- 2009-12-24 IL IL202961A patent/IL202961A/en not_active IP Right Cessation
-
2010
- 2010-01-07 TN TNP2010000008A patent/TN2010000008A1/fr unknown
- 2010-01-07 MA MA32485A patent/MA31507B1/fr unknown
- 2010-01-12 CO CO10002343A patent/CO6270204A2/es active IP Right Grant
- 2010-01-12 EC EC2010009871A patent/ECSP109871A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR067630A1 (es) | 2009-10-21 |
| WO2009007426A1 (en) | 2009-01-15 |
| IL202961A (en) | 2013-10-31 |
| AU2008274170A1 (en) | 2009-01-15 |
| PE20130180A1 (es) | 2013-03-06 |
| KR20100029829A (ko) | 2010-03-17 |
| CN101686938B (zh) | 2012-09-05 |
| NZ582443A (en) | 2011-04-29 |
| RU2493826C2 (ru) | 2013-09-27 |
| MY147366A (en) | 2012-11-30 |
| JP5314014B2 (ja) | 2013-10-16 |
| EP2178503A1 (en) | 2010-04-28 |
| US20100197629A1 (en) | 2010-08-05 |
| TW200911302A (en) | 2009-03-16 |
| CL2008002025A1 (es) | 2009-05-08 |
| MA31507B1 (fr) | 2010-07-01 |
| CA2693609A1 (en) | 2009-01-15 |
| CN101686938A (zh) | 2010-03-31 |
| PE20090476A1 (es) | 2009-05-12 |
| RU2010104395A (ru) | 2011-08-20 |
| KR20120078754A (ko) | 2012-07-10 |
| KR20140019040A (ko) | 2014-02-13 |
| BRPI0815562A2 (pt) | 2015-02-18 |
| US8445457B2 (en) | 2013-05-21 |
| ECSP109871A (es) | 2010-02-26 |
| AU2008274170B2 (en) | 2011-06-09 |
| JP2010533146A (ja) | 2010-10-21 |
| TN2010000008A1 (en) | 2011-09-26 |
| ZA200908993B (en) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2244831T5 (es) | Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica | |
| MA28921B1 (fr) | Derive heterocyclique azote et medicament le contenant en tant que principe actif | |
| DE60137399D1 (de) | Propansäurederivate die die Bindung von Integrinen an ihre Rezeptoren hemmen | |
| UY27300A1 (es) | Nuevos derivados de quinolina | |
| CO6270204A2 (es) | Soluciones farmaceuticas orales que contienen telbivudina | |
| BR0207726A (pt) | Sais farmacêuticos | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| CR8411A (es) | Metodo para el tratamiento de la enfermedad asociada con adamts-5 | |
| BR0308188A (pt) | Forma de administração a ser aplicada oralmente, para substâncias ativas básicas de difìcil solubilidade | |
| ATE469674T1 (de) | 5-aminolävulinsäure-derivate zur behandlung von akne | |
| RS50534B (sr) | Intranazalna formulacija rotigotina | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| UY27646A1 (es) | Derivados de quinolina como antagonistas de npt | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| PT96506A (pt) | Processo para a preparacao de composicoes orais que incorporam como ingrediente activo pimobendano | |
| NO20022201L (no) | Lösninger inneholdende Epinastin | |
| ATE212837T1 (de) | Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure | |
| PE20011223A1 (es) | Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico | |
| BRPI0412697A (pt) | composições farmacêuticas que apresentam um revestimento expansìvel | |
| BRPI0410044A (pt) | forma de dosagem contendo pantoprazol como ingrediente ativo | |
| FR2848851B1 (fr) | Procede d'obtention d'un principe actif presentant des capacites apaisantes, principe actif et compositions obtenues | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| ATE340570T1 (de) | 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon | |
| BR0008368A (pt) | Derivados fenilalaninol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |